European Companies Search Engine

Quick Search Power Search
Tips & Tricks
Our help pages Using the Quick Search and Power Search Overview explain how to use our search engine.

Lionex GmbH, Braunschweig, Germany

Watch

If you put a company on your watch list, we'll notify you on your email address when there are new publications regarding this company.

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Dossier

The dossier is a printable PDF file, summarizing information and publications for this company. The creation of dossiers is included in your subscription. After the creation of the dossier is completed, it will be sent to your email address .

Add to dossier (if available):

This feature is only available to our premium service subscribers.

Learn more about the North Data Premium Service

Name

Lionex GmbH

Register

Ut
District Court of Braunschweig HRB 4884

Address

Salzdahlumer Str. 196, Gebäude 1 A, 38126 Braunschweig, Germany

Corporate purpose

The development and manufacture of special biotechnological products for medical diagnostics, vaccine development and therapy to combat various diseases of humans and animals.

Financials

Earnings Revenue

Earnings

For this company, Earnings numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

Revenue

For this company, Revenue numbers are only available to our premium service subscribers.

Learn more about the North Data Premium Service

History

Marketing & Tech

Network

Loading network

JOBS AT NORTH DATA

  • Modern Java Developer

Publications

9 Apr 2024
Annual report for the year ending 31/12/2022 · Balance sheet for 31/12/2022
21 Jun 2023
Annual report for the year ending 31/12/2021 · Balance sheet for 31/12/2021
28 Jul 2022
Managing Director: Maximilian W. Singh · No longer Officer: Wulf Oehlmann
24 Feb 2022
Annual report for the year ending 31/12/2020 · Balance sheet for 31/12/2020
1 Nov 2021 in Fk
Public funding (€183,000): Time-resolved fluorescence detection for the integrated multiparameter analysis of multi-resistance exemplary in tuberculosis (FluoResYst) - Subproject: Research and …
1 May 2021 in Fk
Public funding (€297,930): A cost-effective and broadly applicable mimetop-based diagnostic platform for highly threatening pandemics, subproject: Development and performance evaluation of magnetic …
20 Jan 2021
Annual report for the year ending 31/12/2019 · Balance sheet for 31/12/2019
8 Dec 2020
Original document: “Liste der Gesellschafter“
8 Dec 2020
Share­holder agreement
29 Oct 2020
Original document: “Gesellschaftsvertrag / Satzung / Statut“
1 Aug 2020 in Fk
Public funding (€147,868): Demonstration of a novel validated mark-free multiplex biosensor system for the fiber optic detection of water-borne pathogens, sub-projects: product development process ( …
28 Apr 2020
Share­holder agreement
6 Feb 2020
Annual report for the year ending 31/12/2018 · Balance sheet for 31/12/2018
1 Jan 2020 in Fts
EU funding (€122,951): 847762 - SMA-TB - a Novel Stratified Medicine Algorithm to Predict Treatment Responses to Host-Directed Therapy in TB Patients.
1 Jan 2020 in Fts
EU funding (€1,955.30): 847762 - SMA-TB - a Novel Stratified Medicine Algorithm to Predict Treatment Responses to Host-Directed Therapy in TB Patients.
1 Jan 2020 in Hor
EU funding (€124,905): A novel Stratified Medicine Algorithm to predict treatment responses to host-directed therapy in TB patients.
1 Oct 2019 in Fts
EU funding (€240,148): 860325 - Bactivax - Anti-Bacterial Innovative Vaccine Training Network.
1 Oct 2019 in Fts
EU funding (€12,639.35): 860325 - Bactivax - Anti-Bacterial Innovative Vaccine Training Network.
28 Aug 2019 in Hor
EU funding (€252,788): anti-Bacterial Innovative Vaccine Training Network.
10 Apr 2019
Officer: Wulf Oehlmann · Address
18 Jan 2019
Annual report for the year ending 31/12/2017 · Balance sheet for 31/12/2017
16 Apr 2018
Wordmark: “LIOFeron“
27 Dec 2017
Patent: Status of Tuberculosis Infection in an Individual
10 Oct 2017
Annual report for the year ending 31/12/2016 · Balance sheet for 31/12/2016
12 Jan 2017
Annual report for the year ending 31/12/2015 · Balance sheet for 31/12/2015
13 Dec 2016
Patent: Novel Human Bladder Cancer Biomarkers and Their Diagnostic USE
1 Aug 2016 in Fk
Public funding (€184,386): Marking-free multiplex biosensor system based on fiber optic arrays for the detection of water-transferable pathogens (Multi-WAP), sub-projects: Lionex
7 Jul 2016
Wordmark: “LIODROP“
15 Apr 2016 via LIONEX Diagnostics and Therapeutics GmbH
Patent: A Novel Substrate and Device for Detecting an Analyte and Method for Rapid Diagnosis
17 Nov 2015
Patent: Device for USE in Elispot
1 Oct 2015 in Fk
Public funding (€285,997): Back to culture: Rapid detection of multi-resistant germs by cultivation on optofluidic diffraction structures - Sub-projects: Development of the basis for measuring …
28 Aug 2015
Annual report for the year ending 31/12/2014 · Balance sheet for 31/12/2014
8 Apr 2015
Wordmark: “LIOdetect“
8 Apr 2015
Wordmark: “LIOKine“
8 Apr 2015
Wordmark: “LIOSpot“
5 Jan 2015
Annual report for the year ending 31/12/2013 · Balance sheet for 31/12/2013
1 Jan 2015 in Fts
EU funding (€387,685): 643558 - EMI-TB - Eliciting Mucosal Immunity to Tuberculosis
1 Jan 2015 in Hor
EU funding (€408,350): Eliciting Mucosal Immunity to Tuberculosis
23 Jan 2014
Patent: Status of tuberculosis infection in an individual
7 Jan 2014
Annual report for the year ending 31/12/2012 · Balance sheet for 31/12/2012
1 Jan 2014 in Fts
EU funding: Grant FP7 - 604048 - IP4Plasma
1 Jan 2014 in Fts
EU funding: Grant FP7 - 604048 - IP4Plasma
Year 2013 in Epobase
4 European patent filings: Combination of Ethambutol with AT Least ONE Additional Anti-Bacterial Agent for USE in the Treatment of Bacterial Infections …
Year 2013 in Fts
5 EU fundings (total €427,612): Fast, Cost-Effective, User-Friendly Point of Care (POC) Instrument for Detection of Respiratory Pathogens, Including Streptococcus Pneumoniae …
11 Dec 2012 via LIONEX Diagnostics and Therapeutics GmbH
Patent: Compositions for use in the Treatment of Bacterial Infections
1 Nov 2012 in Fts
EU funding (€809,254): Multimodular Biomarker Analysis Workflow for Diagnosis, Prognosis and Monitoring of Drug Treatment Response in Bladder Cancer
21 Sept 2012 via LIONEX Diagnostics and Therapeutics GmbH
Patent: Mycobacterial Thiolperoxidase and its use
16 Jul 2012
Patent: Status of Tuberculosis Infection in an Individual
1 Mar 2012 in Fk
Public funding (€161,742): SME-innovative-8: Production of an innovative low-cost rapid test for tuberculosis detection - 'Inno-TB'
1 Sept 2011 in Fts
EU funding (€230,877): FP7-SME-2011-SME-286798-Caphiv-Early Detection of HIV-1 Using Ultra-Sensitive, Rapid Capacitive Biosensor
20 Jan 2011
Annual report for the year ending 31/12/2009 · Balance sheet for 31/12/2009
Year 2010 in Fts
4 EU fundings (total €742,465): Systemtb …
25 Nov 2009
Annual report for the year ending 31/12/2008 · Balance sheet for 31/12/2008
29 Apr 2009
Annual report for the year ending 31/12/2007 · Balance sheet for 31/12/2007
8 Apr 2008
Annual report for the year ending 31/12/2006 · Balance sheet for 31/12/2006
1 Mar 2007 as LIONEX DIAGNOSTICS & THERAPEUTICS GmbH
EU funding (€1,217,800): Development and Clinical Evaluation of Fast Tests for Tuberculosis Diagnosis
21 Sept 2005
Patent: Vector Comprising Mycobacterium Tuberculosis 38 kDa Antigen for Neoplasm Treatment
6 Sept 2005
Reg­is­tra­tion · Managing Director: Mahavir Singh · Capital: €25,000 · Seat: Braunschweig, Germany · Legal form: GmbH · Name: Lionex GmbH · Corporate Purpose
23 Mar 2005
Patent: Test Kit for Tuberculosis Diagnosis or the Like

The data on this page is generated by a fully automated algorithm. It may have errors, and is provided on an "as is" basis with no guarantees of completeness, accuracy, usefulness or timeliness.

Creative Commons License The visualizations for "Lionex GmbH, Braunschweig, Germany" are provided by North Data and may be reused under the terms of the Creative Commons CC-BY license.

Printing is only available to North Data premium service subscribers.
Close